09 August 2019 | News
The 5,000-sqm facility, built by Dalian Municipal Government, will support Lion TCR's development and commercialisation of cell therapy products in China in addition to Lion TCR's facility at the China-Singapore Guangzhou Knowledge City
Image Credit: pharmaphorum.com
Lion TCR Pte. Ltd., a Singapore based clinical-stage Biotech company focused on development of innovative engineered T cell immunotherapy against viral-related cancer and chronic Hepatitis B infection, announced on 29 July 2019 that it has signed an agreement with Dalian Lvshun District Government at the 10th Singapore-Liaoning Economic and Trade Council Meeting (SLETC) to develop cell manufacturing and research facilities for cancer treatment.
The 5,000-sqm facility, built by Dalian Municipal Government, will support Lion TCR's development and commercialisation of cell therapy products in China in addition to Lion TCR's facility at the China-Singapore Guangzhou Knowledge City. Lion TCR shall utilize GMP (Good Manufacturing Practice) certified entities for the production of advanced cellular immunotherapy products for clinical trials and for future commercial products. The facility design and process will comply with both China CDE and internationally recognized GMP guidelines.
The 10th SLETC was chaired by Mr. Masagos Zulkifli, Singapore's Minister for the Environment and Water Resources, and Mr. Tang Yijun, Liaoning Governor, the Co-Chairmen of SLETC. At the council meeting, 11 Singapore companies including Lion TCR signed project agreements to provide greater connectivity, sustainability, technology and healthcare in Liaoning. Singapore is Liaoning's third largest foreign investor with a total investment of about S$19 billion (95 billion yuan).
Mr Stephen Lim, CEO of Lion TCR commented that "Lion TCR looks forward to using this Dalian GMP cell therapy facilities as a manufacturing base for our China commercialisation needs. As a stand-alone building is required for cell therapy GMP application in China, this offer to build with option for Lion to purchase by the Dalian Government is a great help to Lion as it frees our immediate cashflow for continual research and on-going clinical trials."